# An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

> **NCT04950764** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 24 (actual)

## Conditions studied

- Primary Biliary Cholangitis
- Compensated Cirrhosis
- Hepatic Impairment

## Interventions

- **DRUG:** Seladelpar

## Key facts

- **NCT ID:** NCT04950764
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-27
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04950764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04950764, "An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04950764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*